Fig. 1: Survival outcomes and clinical courses with venetoclax treatment.
From: Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia
Overall survival of all patients from the start of venetoclax treatment (A) White blood cells (WBC) during venetoclax and bendamustine dosing among patients who experienced clinical response (bottom panels): Patient #6 (B), Patient #7 (C), Patient #8 (D), Patient #9 (E).
